USARx offers the following ways to purchase this medication. Choose the Best option for you!
Commonly reported side effects of repaglinide include: hypoglycemia. See below for a comprehensive list of adverse effects.For the Consumer
Applies to repaglinide: oral tablet
Along with its needed effects, repaglinide may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking repaglinide:
Incidence not known
Some side effects of repaglinide may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Incidence not known
For Healthcare Professionals
Applies to repaglinide: oral tabletGeneral
The most frequently reported adverse reactions were changes in blood glucose levels; the occurrence of these reactions was dependent on individual factors such as dietary habits, dose, exercise, and stress.Metabolic
Very common (10% or more): Hypoglycemia (up to 31%)
In 12 to 24 week clinical trials, hypoglycemia occurred in 31% of patients receiving this drug compared to 7% of placebo-treated patients. In 1 year trials, hypoglycemia occurred in 16% of patients receiving this drug compared to 19% and 20% of glipizide and glyburide patients, respectively.Cardiovascular
Cardiovascular events were evaluated in trials comparing this drug to sulfonylureas. Serious cardiovascular events including ischemia with this drug were higher at 4% than for sulfonylurea drugs (3%). No excess mortality was associated with this increase. Selected cardiovascular events including hypertension, abnormal EKG, MI, arrhythmias, and palpitations were observed at 1% or less and no more frequently with this drug than with comparator drugs.
Trials of this drug in combination with NPH insulin found 6 serious events of myocardial ischemia.
Common (1% to 10%): Chest pain, angina, serious cardiovascular events including ischemia
Frequency not reported: Hypertension, abnormal EKG, MI, arrhythmias, palpitationsHypersensitivity
Common (1% to 10%): Allergy
Uncommon (0.1% to 1%): Allergic skin reactions such as rash, urticaria, and pruritus
Frequency not reported: Anaphylactoid reactions
Anaphylactoid reactions were reported in less than 1% of patients. Allergic skin reactions such as rash, urticaria, and pruritus have been observed. There is no reason to suspect cross-allergenicity with sulfonylurea drugs due to the difference in chemical structure.Gastrointestinal
Common (1% to 10%): Nausea, diarrhea, constipation, vomiting, dyspepsia, tooth disorder
Postmarketing reports: PancreatitisNervous system
Very common (10% or more): Headache (up to 11%)
Common (1% to 10%): ParesthesiaMusculoskeletal
Common (1% to 10%): Arthralgia, back painRespiratory
Very common (10% or more): Upper respiratory infection (up to 16%)
Common (1% to 10%): Sinusitis, rhinitis, bronchitisHepatic
Postmarketing experience has included reports of severe hepatic dysfunction including jaundice and hepatitis.
Frequency not reported: Elevated liver enzymes
Postmarketing reports: Severe hepatic dysfunction including jaundice and hepatitisHematologic
Thrombocytopenia or leukopenia have been reported in less than 1% of patients.
Frequency not reported: Thrombocytopenia, leukopenia
Postmarketing reports: Hemolytic anemiaOcular
Rare (less than 0.1%): Blurred vision
Very rare (less than 0.01%): Refraction disorder
Refraction disorders have been known to result due to changes in blood glucose levels.Dermatologic
Postmarketing reports: Alopecia, Stevens-Johnson syndromeGenitourinary
Common (1% to 10%): Urinary tract infection
August 6, 2020
August 6, 2020
March 31, 2021
March 29, 2021
March 27, 2021
January 25, 2021